Voyager Therapeutics Inc (VYGR) 13F Holdings Overview (Q2 2026)

VYGR ranks #3860 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

VYGR is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

139 institutions disclose a position in VYGR, but none treat it as a major bet — even Opaleye Management Inc., its most concentrated holder, allocates just 0.4% of its own portfolio to it.

Israel Englander has added to its VYGR position for two straight quarters, increasing it by $8.0M to reach $15.6M today.

BlackRock has trimmed its VYGR position for two straight quarters, cutting it by $4.0M while still holding $18.1M.

VYGR is up 2.3% today, and institutions have been net buyers of $8.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VYGR reported a net loss of $107.7M over the trailing twelve months.

• Not yet profitable — net loss of $107.7M over the trailing twelve months
• Revenue declined 19.1% year over year
• Net income improved year over year, from -$107.9M to -$107.7M
• Operating cash flow was negative, using $132.5M in cash
• Current ratio of 7.64x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.29x equity — within a conventional range